We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+6.67%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$424M
AUM Growth
+$63.8M
(+18%)
Cap. Flow
+$75.3M
Cap. Flow
% of AUM
17.76%
Top 10 Holdings %
Top 10 Hldgs %
48.45%
Holding
91
New
14
Increased
28
Reduced
11
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUVL
Nuvalent
NUVL
|
+$21.9M |
| 2 |
Erasca
ERAS
|
+$16.4M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$10.9M |
| 4 |
UroGen Pharma
URGN
|
+$8.44M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$7.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perspective Therapeutics
CATX
|
+$7.96M |
| 2 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$7.89M |
| 3 |
Solid Biosciences
SLDB
|
+$7.63M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$5.98M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$5.83M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Cytokinetics
CYTK
$10.6B
| – | – |
-50,000
| Closed | -$3.51M |
|
77
DexCom
DXCM
$29B
| – | – |
-20,000
| Closed | -$2.77M |
|
78
Immunome
IMNM
$2.62B
| – | – |
-7,489
| Closed | -$185K |
|
79
Krystal Biotech
KRYS
$10.7B
| – | – |
-10,000
| Closed | -$1.78M |
|
80
CALL
MacroGenics
MGNX
$233M
| – | – |
-145,500
| Closed | -$2.14M |
|
81
Mineralys Therapeutics
MLYS
$2.32B
| – | – |
-56,944
| Closed | -$735K |
|
82
NewAmsterdam Pharma
NAMS
$3.26B
| – | – |
-99,612
| Closed | -$2.36M |
|
83
Pliant Therapeutics
PLRX
$65M
| – | – |
-183,392
| Closed | -$2.73M |
|
84
Rocket Pharmaceuticals
RCKT
$343M
| – | – |
-101,002
| Closed | -$2.72M |
|
85
Rezolute
RZLT
$453M
| – | – |
-151,985
| Closed | -$388K |
|
86
Scholar Rock
SRRK
$5.88B
| – | – |
-199,415
| Closed | -$3.54M |
|
|
TERN
87
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-250,551
| Closed | -$1.64M |
|
88
Viking Therapeutics
VKTX
$3.88B
| – | – |
-20,000
| Closed | -$1.64M |
|
89
Xenon Pharmaceuticals
XENE
$6.1B
| – | – |
-66,090
| Closed | -$2.85M |
|
|
BOLD
90
Boundless Bio
BOLD
$55.7M
| – | – |
-312,500
| Closed | -$4.45M |
|
|
ALPN
91
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-199,020
| Closed | -$7.89M |
|
Similar funds
BIP
MVM
MFWP
FCM
PE
KL
GFP
ADIC
Silverarc Capital Management's Q2 2024 Portfolio in Review
As of Q2 2024, Silverarc Capital Management held 91 positions worth $424M, up 18% from $360M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Silverarc Capital Management deployed $75.3M of net new capital in Q2 2024, opening 14 new positions and adding to 28 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier.
On the sell side, the largest reduction was Perspective Therapeutics, an estimated $7.96M trimmed.
- Silverarc Capital Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.
- Silverarc Capital Management added most to Nuvalent in Q2 2024, an estimated $21.9M increase.
- Silverarc Capital Management's biggest Q2 2024 reduction was Perspective Therapeutics, cutting an estimated $7.96M.
- Silverarc Capital Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $7.89M.
- Silverarc Capital Management's ten largest holdings make up 48% of its $424M portfolio in Q2 2024.
- Silverarc Capital Management opened 14 new positions and closed 21 in Q2 2024.
- Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $424M.
Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.